Moderna Inc/ US60770K1079 /
2024-05-28 10:00:00 PM | Chg. -13.4100 | Volume | Bid1:59:04 AM | Ask1:59:04 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
153.2000USD | -8.05% | 6.64 mill. Turnover: 706.24 mill. |
153.0000Bid Size: 200 | 153.3500Ask Size: 100 | 58.71 bill.USD | - | - |
GlobeNewswire
05-22
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn an...
GlobeNewswire
05-12
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
05-02
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-01
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-04
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Aga...
GlobeNewswire
03-04
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024